Robert E. Desjardins

1.2k total citations
18 papers, 948 citations indexed

About

Robert E. Desjardins is a scholar working on Public Health, Environmental and Occupational Health, Pharmacology and Molecular Biology. According to data from OpenAlex, Robert E. Desjardins has authored 18 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Public Health, Environmental and Occupational Health, 5 papers in Pharmacology and 4 papers in Molecular Biology. Recurrent topics in Robert E. Desjardins's work include Malaria Research and Control (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Pharmaceutical studies and practices (4 papers). Robert E. Desjardins is often cited by papers focused on Malaria Research and Control (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Pharmaceutical studies and practices (4 papers). Robert E. Desjardins collaborates with scholars based in United States, Switzerland and China. Robert E. Desjardins's co-authors include J. David Haynes, Carter L. Diggs, Norman F. Weatherly, Jean H. Bowdre, A.M.J. Oduola, Craig J. Canfield, Roger Williams, Paul E. Carson, Gordon M. Trenholme and Karl H. Rieckmann and has published in prestigious journals such as Nature, Science and Blood.

In The Last Decade

Robert E. Desjardins

17 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert E. Desjardins United States 14 451 169 154 116 111 18 948
Fiona Macintyre United Kingdom 11 438 1.0× 305 1.8× 336 2.2× 96 0.8× 275 2.5× 16 1.1k
Farkad Ezzet Switzerland 19 748 1.7× 120 0.7× 387 2.5× 270 2.3× 268 2.4× 27 1.7k
Peter R. Jackson United Kingdom 18 225 0.5× 217 1.3× 136 0.9× 195 1.7× 21 0.2× 37 1.1k
Yuching Yang United States 18 168 0.4× 275 1.6× 426 2.8× 108 0.9× 105 0.9× 33 1.3k
D. Brockmeier Germany 15 268 0.6× 325 1.9× 261 1.7× 55 0.5× 17 0.2× 44 1.2k
Mark Baker Switzerland 14 403 0.9× 108 0.6× 141 0.9× 82 0.7× 155 1.4× 22 757
Lisa M. Almond United Kingdom 17 79 0.2× 158 0.9× 327 2.1× 129 1.1× 77 0.7× 34 1.1k
Nguyễn Văn Hướng Vietnam 13 461 1.0× 73 0.4× 318 2.1× 46 0.4× 228 2.1× 25 736
Trinh Ngoc Hai Sweden 14 410 0.9× 75 0.4× 385 2.5× 46 0.4× 260 2.3× 14 645
Daniel Blessborn Thailand 17 646 1.4× 78 0.5× 185 1.2× 50 0.4× 234 2.1× 28 882

Countries citing papers authored by Robert E. Desjardins

Since Specialization
Citations

This map shows the geographic impact of Robert E. Desjardins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Desjardins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Desjardins more than expected).

Fields of papers citing papers by Robert E. Desjardins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Desjardins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Desjardins. The network helps show where Robert E. Desjardins may publish in the future.

Co-authorship network of co-authors of Robert E. Desjardins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Desjardins. A scholar is included among the top collaborators of Robert E. Desjardins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Desjardins. Robert E. Desjardins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Desjardins, Robert E., et al.. (2006). Single and Multiple Oral Doses of AKR-501 (YM477) Increase the Platelet Count in Healthy Volunteers.. Blood. 108(11). 477–477. 49 indexed citations
2.
Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1994). Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. The Journal of Clinical Pharmacology. 34(2). 111–119. 37 indexed citations
3.
Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Journal of Pharmaceutical Sciences. 81(6). 605–610. 49 indexed citations
4.
Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clinical Pharmacology & Therapeutics. 51(4). 465–473. 141 indexed citations
5.
Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Pharmaceutical Research. 9(6). 826–833. 41 indexed citations
6.
Peck, Carl C., William H. Barr, Leslie Z. Benet, et al.. (1992). Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. International Journal of Pharmaceutics. 82(1-2). 9–19. 7 indexed citations
7.
Shapiro, Theresa A., et al.. (1991). Pharmacokinetics and metabolism of allopurinol riboside. Clinical Pharmacology & Therapeutics. 49(5). 506–514. 18 indexed citations
8.
Oduola, A.M.J., Norman F. Weatherly, Jean H. Bowdre, & Robert E. Desjardins. (1988). Plasmodium falciparum: Cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. Experimental Parasitology. 66(1). 86–95. 121 indexed citations
9.
Cheung, Wing K., et al.. (1988). Importance of Oral Dosing Rate on the Hemodynamic and Pharmacokinetic Profile on Nilvadipine. The Journal of Clinical Pharmacology. 28(11). 1001–1007. 2 indexed citations
10.
Tally, Francis P., et al.. (1987). Safety profile of cefixime. The Pediatric Infectious Disease Journal. 6(10). 976–980. 27 indexed citations
11.
Faulkner, Robert, et al.. (1987). Pharmacokinetics of Cefixime After Once‐a‐Day and Twice‐a‐Day Dosing to Steady State. The Journal of Clinical Pharmacology. 27(10). 807–812. 20 indexed citations
12.
Oduola, A.M.J., et al.. (1985). Use of Non-Human Plasma for in Vitro Cultivation and Antimalarial Drug Susceptibility Testing of Plasmodium Falciparum. American Journal of Tropical Medicine and Hygiene. 34(2). 209–215. 11 indexed citations
13.
Weatherly, Norman F., et al.. (1983). End-tidal exhaled air for the in vitro maintenance of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene. 77(1). 103–105. 6 indexed citations
14.
Cosgriff, Thomas M., et al.. (1982). Evaluation of the Antimalarial Activity of the Phenanthrenemethanol Halofantrine (WR 171,669). American Journal of Tropical Medicine and Hygiene. 31(6). 1075–1079. 46 indexed citations
15.
Desjardins, Robert E., et al.. (1980). Trypanosoma rhodesiense: Semiautomated microtesting for quantitation of antitrypanosomal activity in vitro. Experimental Parasitology. 50(2). 260–271. 21 indexed citations
16.
Smallridge, Robert C., Leonard Wartofsky, Robert E. Desjardins, & Kenneth D. Burman. (1978). Metabolic Clearance and Production Rates of 3,3′,5′- Triiodothyronine in Hyperthyroid, Euthyroid, and Hypothyroid Subjects*. The Journal of Clinical Endocrinology & Metabolism. 47(2). 345–349. 19 indexed citations
17.
Haynes, J. David, et al.. (1976). Culture of human malaria parasites Plasmodium falciparum. Nature. 263(5580). 767–769. 198 indexed citations
18.
Trenholme, Gordon M., Roger Williams, Robert E. Desjardins, et al.. (1975). Mefloquine (WR 142,490) in the Treatment of Human Malaria. Science. 190(4216). 792–794. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026